arrow
E

Evangelos Eleutherakis-Papaiakovou

National and Kapodistrian University of Athens
H指数:32
被引数:2,810

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression of Disease Within 24 Months (POD24) is an Independent Prognostic Factor for Survival in Waldenström Macroglobulinemia

24个月内疾病进展(POD24)是华氏巨球蛋白血症中生存的独立预后因素

2026-08-200
OAAI
Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus

运动训练能否改善多发性骨髓瘤患者的生活质量和身体功能?:探讨训练刺激的进展

Sports
IF2.9
2026-02-040
OAAI
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Belantamab mafodotin、lenalidomide和dexamethasone(BelaRd)在新诊断的中等适合和脆弱型骨髓瘤中

Blood
IF23.1
2025-12-080
PREAI
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma − a single center, retrospective imaging analysis on 119 patients

骨疾病负担不影响新诊断多发性骨髓瘤患者的总生存期——一项基于119例患者的单中心、回顾性影像学分析

2025-10-250
OAAI
Circulating tumor cells by Next Generation Flow Cytometry as a new prognostic biomarker for patients with asymptomatic monoclonal gammopathies

下一代流式细胞术检测的循环肿瘤细胞作为无症状性单克隆丙种球蛋白病患者的新型预后生物标志物

2025-10-210
OA
Pomalidomide, cyclophosphamide and dexamethasone for relapsed/refractory multiple myeloma; a single-center experience

泊马利度胺、环磷酰胺和地塞米松用于复发/难治性多发性骨髓瘤;一项单中心经验

2025-08-050
OAAI
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution

多发性骨髓瘤15年无进展生存的影响因素;单一机构真实世界数据

2025-07-180
OAAI
Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis

胱抑素C作为评价AL淀粉样变性肾结局的生物标志物

2025-05-190
OA
Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring

2014年后确诊的427例冒烟型骨髓瘤患者的进展模式:监测的重要性

2025-04-020
OAAI
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

新诊断且需要透析的多发性骨髓瘤患者的结局

2025-03-040
OAAI
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies
2025-02-040
PRE
Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First-Line Treatment
2025-01-240
OAAI
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

新诊断且需透析的骨髓瘤患者的结局

BLOOD
IF23.1
2024-11-050
PRE
Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma

应用序贯全身磁共振成像评估新诊断多发性骨髓瘤患者的早期治疗效果

BLOOD
IF23.1
2024-11-050
PRE
Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

新诊断多发性骨髓瘤患者中T(11;14)的预后影响:现代治疗时代的分析

BLOOD
IF23.1
2024-11-050
PRE
Bone Disease Burden Does Not Seem to Impact Overall Survival in Newly Diagnosed Patients with Multiple Myeloma- a Detailed Imaging Analysis on 119 Patients

骨髓瘤新诊断患者中,骨病负担似乎不影响总生存期——一项针对119例患者的详细影像学分析

BLOOD
IF23.1
2024-11-050
PRE
Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

真实世界环境下接受不同方案治疗的连续新诊断华氏巨球蛋白血症患者的临床结局

BLOOD
IF23.1
2024-11-050
PRE
Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes

连续全身低剂量CT扫描可在冒烟型多发性骨髓瘤患者中识别早期进展,并可能改善患者预后。

BLOOD
IF23.1
2024-11-050
PRE
Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

基于抗CD38的四联疗法作为新诊断多发性骨髓瘤诱导治疗的比较

BLOOD
IF23.1
2024-11-050
PRE